ESC Premium Access

Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

Congress Presentation

About the speaker

Doctor Milan Gupta

University of Toronto, Toronto (Canada)
0 follower

53 more presentations in this session

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Speaker: Doctor A. Tyminska (Warsaw, PL)

Thumbnail

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Speaker: Professor H. Bonnemeier (Luebeck, DE)

Thumbnail

Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Speaker: Ms D. Loikas (Stockholm, SE)

Thumbnail

Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Speaker: Doctor J. Franchino-Elder (Ridgefield, US)

Thumbnail

Real-world single tertiary-care multidisciplinary experience with dabigatran, apixaban, rivaroxaban and warfarin in patients with renal failure and concomitant NVAF.

Speaker: Doctor F. Melillo (Milan, IT)

Thumbnail

Access the full session

Poster session 4 - Stroke prevention

Speakers: Doctor M. Gupta, Doctor A. Tyminska, Professor H. Bonnemeier, Ms D. Loikas, Doctor J. Franchino-Elder...
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb